13 results
10-K
2021 FY
EX-10.20
GLUE
Monte Rosa Therapeutics Inc
29 Mar 22
Annual report
4:15pm
Lender whose consent is required thereunder withholds its consent, or if the Transfer is to a transferee, assignee or sublessee of poor reputation
10-K
2021 FY
GLUE
Monte Rosa Therapeutics Inc
29 Mar 22
Annual report
4:15pm
to fines, injunctions or imposition of criminal penalties; and
our reputation may suffer.
We believe that any of these events could prevent us from … in:
decreased demand for any current or future product candidates that we may develop;
injury to our reputation and significant negative media attention
10-Q
2021 Q2
GLUE
Monte Rosa Therapeutics Inc
12 Aug 21
Quarterly report
4:22pm
;
we may be subject to fines, injunctions or imposition of criminal penalties; and
our reputation may suffer.
We believe that any of these events … outcome, liability claims may result in:
decreased demand for any current or future product candidates that we may develop;
injury to our reputation
424B4
yswl3yv8
25 Jun 21
Prospectus supplement with pricing info
6:08am
S-1/A
ly80y1 ku
9 Jun 21
IPO registration (amended)
4:51pm
S-1
gfgo3mscgeu2s01 3p3b
4 Jun 21
IPO registration
9:07am
S-1
EX-10.19
ssoi1405tzvf
4 Jun 21
IPO registration
9:07am
DRS/A
t00eue3l
21 May 21
Draft registration statement (amended)
12:00am
DRS
lgar1wvs 9w9w
19 Apr 21
Draft registration statement
12:00am
DRS
EX-10.18
yta ch3sgefrsgx
19 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next